Trial Profile

A Phase II Study to Evaluate Safety and Efficacy of Neo-adjuvant Pembrolizumab and Radiotherapy in Localised MSS Rectal Cancer

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 10 Aug 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pembrolizumab (Primary)
Indications Adenocarcinoma; Rectal cancer
Focus Therapeutic Use
Acronyms PEMREC

Most Recent Events

15 Jul 2022 Trial design presented at the BMC Cancer.
04 Jul 2020 According to trial design details presented at the 22nd World Congress on Gastrointestinal Cancer, a safety stopping rule is planned based on Walds sequential probability ratio test for the occurrence of the safety outcome.
04 Jul 2020 Trial design details of this trial, were presented at the 22nd World Congress on Gastrointestinal Cancer.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com